Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e000987
Publisher
BMJ
Online
2020-08-27
DOI
10.1136/jitc-2020-000987
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
- (2020) Sohyun Hwang et al. Scientific Reports
- Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
- (2019) Joe Yeong et al. Journal for ImmunoTherapy of Cancer
- PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
- (2019) Vivek Verma et al. NATURE IMMUNOLOGY
- Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence
- (2019) Chi Peng Timothy Lai et al. BREAST CANCER RESEARCH AND TREATMENT
- The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach
- (2019) An Sen Tan et al. VIRCHOWS ARCHIV
- Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma
- (2019) Jian Hang Lam et al. Frontiers in Immunology
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
- (2019) Lichun Ma et al. CANCER CELL
- Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
- (2019) Andrew B. Nixon et al. Journal for ImmunoTherapy of Cancer
- Adenosine Metabolism: Emerging Concepts for Cancer Therapy
- (2019) Detlev Boison et al. CANCER CELL
- CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
- (2019) Hiroshi Kagamu et al. Cancer Immunology Research
- The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
- (2019) Yu Jun Wo et al. Cells
- PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
- (2018) Margarita Udall et al. Diagnostic Pathology
- Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
- (2018) Chun Jye Lim et al. GUT
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer
- (2018) Joe Yeong et al. Frontiers in Immunology
- CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions
- (2018) Stephanie A. Amici et al. Frontiers in Immunology
- An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours
- (2018) Yu Ting Felicia Wee et al. Annals of Diagnostic Pathology
- RNA-Seq analyses of immune cell-type enrichments in 158 Asian colorectal cancers (CRCs).
- (2018) Iain BeeHuat Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- (2018) Yannick Simoni et al. NATURE
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations
- (2018) Sonya A. MacParland et al. Nature Communications
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women
- (2017) Joe Yeong et al. JOURNAL OF CLINICAL PATHOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
- (2017) Si-Rui Ma et al. Molecular Cancer
- FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
- (2017) Lee Pai‐Scherf et al. ONCOLOGIST
- Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma
- (2017) Elizabeth L. Yanik et al. JAMA Oncology
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level
- (2017) et al. JAMA Oncology
- Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer
- (2016) Hirofumi Matsumoto et al. BREAST CANCER RESEARCH AND TREATMENT
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Molecular Pathways: Mucins and Drug Delivery in Cancer
- (2016) Chinthalapally V. Rao et al. CLINICAL CANCER RESEARCH
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Multispectral Imaging of T and B Cells in Murine Spleen and Tumor
- (2016) Zipei Feng et al. JOURNAL OF IMMUNOLOGY
- PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer
- (2016) Seiichi Ikeda et al. Journal of Thoracic Oncology
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
- (2016) Joohee Sul et al. ONCOLOGIST
- The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis
- (2016) Bernhard Mlecnik et al. Science Translational Medicine
- Nomogram for preoperative estimation of long-term survival of patients who underwent curative resection with hepatocellular carcinoma beyond Barcelona clinic liver cancer stage A1
- (2016) Dan-Yun Ruan et al. Oncotarget
- A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
- (2016) Akio Ohta Frontiers in Immunology
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
- (2016) Claud Grigg et al. Journal for ImmunoTherapy of Cancer
- Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic Target
- (2015) Simone Burgler CRITICAL REVIEWS IN IMMUNOLOGY
- Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma
- (2015) Marta Garnelo et al. GUT
- G-protein-independent coupling of MC4R to Kir7.1 in hypothalamic neurons
- (2015) Masoud Ghamari-Langroudi et al. NATURE
- Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis
- (2015) Sara Lovisa et al. NATURE MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological mechanisms of the antitumor effects of supplemental oxygenation
- (2015) Stephen M. Hatfield et al. Science Translational Medicine
- NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
- (2015) Alberto Horenstein et al. Cells
- Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
- (2014) D. Mittal et al. CANCER RESEARCH
- ANGPTL8/Betatrophin Does Not Control Pancreatic Beta Cell Expansion
- (2014) Viktoria Gusarova et al. CELL
- Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression
- (2014) E. Jason Abel et al. HUMAN PATHOLOGY
- Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis
- (2014) Edward C. Stack et al. METHODS
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
- (2013) Z. Kan et al. GENOME RESEARCH
- CD38 Controls the Innate Immune Response against Listeria monocytogenes
- (2013) Timo Lischke et al. INFECTION AND IMMUNITY
- Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors
- (2013) Paul A. Beavis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclic ADP-ribose and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) as Messengers for Calcium Mobilization
- (2012) Hon Cheung Lee JOURNAL OF BIOLOGICAL CHEMISTRY
- The Role of CD38 in Fcγ Receptor (FcγR)-mediated Phagocytosis in Murine Macrophages
- (2012) John Kang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry
- (2012) Christopher Fiore et al. JOURNAL OF CLINICAL PATHOLOGY
- Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
- (2011) Adam T. Waickman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model
- (2011) Jeng-Wei Lu et al. CARCINOGENESIS
- NAD+ -metabolizing ecto-enzymes shape tumor-host interactions: The chronic lymphocytic leukemia model
- (2011) Tiziana Vaisitti et al. FEBS LETTERS
- Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma
- (2011) Valerie Chew et al. GUT
- Extracellular adenosine triphosphate and adenosine in cancer
- (2010) J Stagg et al. ONCOGENE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started